


Nanopass Technologies Revenue
Medical Equipment Manufacturing • Nes Ziona, Center District, Israel • 11-20 Employees
Nanopass Technologies revenue & valuation
| Annual revenue | $8,000,000 |
| Revenue per employee | $400,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Medical Equipment Manufacturing industry and current estimated revenues | $25,600,000 |
| Total funding | $10,500,000 |
Key Contacts at Nanopass Technologies
Daniel Levitats
Chief Executive Officer
Rony Glass
Director Of Marketing And Education
Yoav Hamisha
Director Of R&D And Operatios
Efrat Kochba
Medical Director
Ayala Kamil
Qa/Ra Director
Company overview
| Headquarters | Nes Ziona, Center District, Israel |
| Phone number | +97289462905 |
| Website | |
| NAICS | 3391 |
| SIC | 283 |
| Keywords | Health, Innovation, Aesthetics, Cosmetic, Needles, Vaccine, Microneedle, Intradermal |
| Founded | 2000 |
| Employees | 11-20 |
| Socials |
Nanopass Technologies Email Formats
Nanopass Technologies uses 2 email formats. The most common is {first name} (e.g., john@nanopass.com), used 73.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name} | john@nanopass.com | 73.3% |
{first initial} | j@nanopass.com | 26.7% |
About Nanopass Technologies
NanoPass is where cutting-edge technology intersects with healthcare innovation. We pioneer revolutionary solutions in intradermal delivery, reshaping the landscape of therapeutic and medical aesthetic procedures using our proprietary technology towards a precise, safe, and efficient future. Our MicronJet™ intradermal delivery product platform has redefined the standard of care. Join the Intradermal precision revolution! NanoPass's IP-backed product, the MicronJet (registered with the US FDA, the EU, Brazil, China, Australia and other countries), is the most advanced hollow microneedles device available today. Its excellent performance is backed by more than 50 clinical studies. The Company has concluded the world's first intradermal pandemic flu vaccine study and additional seasonal flu studies, demonstrating equivalent or superior immunogenicity to standard delivery using only 20% of the dose. The company is backed by prominent Israeli and US investors Ă˝and medical device companies, including IHCV, Ofer Hi-Tech, D-Partners, WFD Ventures and Elcam Medical. NanoPass recently closed a new round of financing, led by Israel Health Care Ventures (IHCV) NanoPass is continuously engaged in joint clinical development with top pharmaceutical companies, to demonstrate the benefits of its technology for various indications.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Nanopass Technologies has 10 employees across 4 departments.
Departments
Number of employees
Funding Data
Explore Nanopass Technologies's funding history, including investment rounds, total capital raised, and key backers.
Nanopass Technologies Tech Stack
Discover the technologies and tools that power Nanopass Technologies's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Maps
CDN
UI frameworks
JavaScript libraries
Miscellaneous
Programming languages
Blogs
CRM
Analytics
Frequently asked questions
4.8
40,000 users



